Monitoring targeted therapy using dual-energy CT: Semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases

Cancer Imaging

Volumn 13, Issue 3, 2013, Pages 306-313

  Uhrig, M ^a   Sedlmair, M ^b   Schlemmer, H P ^a   Hassel, J C ^a   Ganten, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b SIEMENS AG   (Germany)

Author keywords

Drug monitoring; Dual energy computed tomography; Melanoma; Spiral computed tomography; Targeted molecular therapy

Indexed keywords

IODINE; VEMURAFENIB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG UPTAKE; DUAL ENERGY COMPUTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MELANOMA; METASTASIS; PATIENT MONITORING; RADIATION DOSE;

ADULT; AGED; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; HUMANS; INDOLES; IODINE; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883064541     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0031     Document Type: Article

References (33)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857. doi:10.1038/nature05661. PMid:17314971.
2. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9. doi:10.1016/j.clindermatol.2008.09.001. PMid:19095149.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206. doi:10.1200/JCO.2009.23.4799. PMid:19917835.
4. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24. doi:10.1634/theoncologist.2010-0190. PMid:21212434.
5. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011; 10: 811-812. doi:10.1038/nrd3579. PMid:22037033.
6. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-599. doi:10.1038/nature09454. PMid:20823850.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. doi:10.1038/nature00766. PMid:12068308. (Pubitemid 34716871)
8. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819. doi:10.1056/NEJMoa1002011. PMid:20818844.
9. Figueiras RG, Padhani AR, Goh VJ, et al. Novel oncologic drugs: what they do and how they affect images. Radiographics 2011; 31: 2059-2091. doi:10.1148/rg.317115108. PMid:22084189.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247. doi:10.1016/j.ejca.2008.10.026. PMid:19097774.
11. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13(Suppl 2): 4-7. doi:10.1634/theoncologist. 13-S2-4. PMid:18434631.
12. Rombola F, Caravetta A, Mollo F, Spinoso A, Peluso L, Guarino R. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. Acta Medica (Hradec Kralove) 2011; 54: 177-179.
13. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-745. doi:10.1038/nrd2380. PMid:-17690708. (Pubitemid 47338181)
14. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010; 34: 479-484. doi:10.1097/RCT.0b013e3181db2670. PMid:-20657213.
15. Joo I, Lee JM, Kim KW, Klotz E, Han JK, Choi BI. Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans: evaluation of the hemodynamic features and correlation with the chemotherapy response. Eur J Radiol 2011; 80: e278-283. doi:10.1016/j.ejrad-. 2010.12.002. PMid:21251785.
16. Johnson TR, Krauss B, Sedlmair M, et al. Material differentiation by dual energy CT: initial experience. Eur Radiol 2007; 17: 1510-1517. doi:10.1007/s00330-006-0517-6. PMid:17151859. (Pubitemid 46767599)
17. Petersilka M, Bruder H, Krauss B, Stierstorfer K, Flohr TG. Technical principles of dual source CT. Eur J Radiol 2008; 68: 362-368. doi:10.1016/j.ejrad.2008.08.013. PMid:18842371.
18. Graser A, Johnson TR, Hecht EM, et al. Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology 2009; 252: 433-440. doi:10.1148/radiol.2522080557. PMid:-19487466.
19. Graser A, Johnson TR, Chandarana H, Macari M. Dual energy CT: preliminary observations and potential clinical applications in the abdomen. Eur Radiol 2009; 19: 13-23. doi:10.1007/s00330-008-1122-7. PMid:18677487.
20. Okada M, Kim T, Murakami T. Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.). Abdom Imaging 2011; 36: 273-281. doi:10.1007/s00261-011-9684-2. PMid:-21267563.
21. Lee SH, Lee JM, Kim KW, et al. Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps. Invest Radiol 2011; 46: 77-84. doi:10.1097/RLI.0b013e3181f23fcd. PMid:20856125.
22. Bundesamt f ur Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte f ur diagnostische und interventionelle Rontgenuntersuchungen, http://www.bfs.de/de/ion/medizin/diagnostik/ referenzwerte.html.
23. Wolchok JD, Hoos A, O-Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420. doi:10.1158/1078-0432.CCR-09-1624. PMid:19934295.
24. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516. doi:10.1056/NEJMoa-1103782. PMid:21639808.
25. Miles KA, Cuenod CA. Multidetector computed tomography in oncology CT perfusion imaging. London, UK: Informa Healthcare; 2007.
26. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 2009; 4: e4771. doi:10.1371/journal.pone.0004771. PMid:19274086.
27. Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33: 237-247. doi:10.1016/j.molcel.2008.12.026. PMid:19187764.
28. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867. doi:10.1016/S0092-8674(04)00215-6. PMid:15035987. (Pubitemid 38410730)
29. Mangold S, Thomas C, Fenchel M, et al. Virtual nonenhanced dual-energy ct urography with tin-filter technology: determinants of detection of urinary calculi in the renal collecting system. Radiology 2012; 264: 119-125. doi:10.1148/radiol.12110851. PMid:22570506.
30. Guggenberger R, Gnannt R, Hodler J, et al. Diagnostic performance of dual-energy CT for the detection of traumatic bone marrow lesions in the ankle: comparison with MR imaging. Radiology 2012; 264: 164-173. doi:10.1148/radiol. 12112217. PMid:22570505.
31. Apfaltrer P, Meyer M, Meier C, et al. Contrast-enhanced dualenergy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response? Invest Radiol 2012; 47: 65-70. doi:10.1097/RLI. 0b013e31823003d2. PMid:21934517.
32. Schramm N, Schlemmer M, Englhart E, et al. Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: initial results. Curr Pharm Biotechnol 2011; 12: 547-557. doi:10.2174/ 138920111795164066. PMid:21342100.
33. Chandarana H, Megibow AJ, Cohen BA, et al. Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. AJR Am J Roentgenol 2011; 196: W693-700. doi:10.2214/AJR.10.5541. PMid:21606256.